Home/Filings/4/0002034671-25-000003
4//SEC Filing

Mazumdar Claire 4

Accession 0002034671-25-000003

CIK 0002023658other

Filed

Oct 14, 8:00 PM ET

Accepted

Oct 15, 6:00 PM ET

Size

14.3 KB

Accession

0002034671-25-000003

Insider Transaction Report

Form 4
Period: 2025-10-13
Mazumdar Claire
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    2025-10-13$18.92/sh11,445$216,545309,892 total
  • Sale

    Common Stock

    2025-10-15$18.84/sh13,289$250,391309,892 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-10-1311,445314,662 total
    Exercise: $3.79Exp: 2033-08-08Common Stock (11,445 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-10-1513,289301,373 total
    Exercise: $3.79Exp: 2033-08-08Common Stock (13,289 underlying)
  • Exercise/Conversion

    Common Stock

    2025-10-13$3.79/sh+11,445$43,374321,337 total
  • Exercise/Conversion

    Common Stock

    2025-10-15$3.79/sh+13,289$50,363323,181 total
Footnotes (4)
  • [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.635, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  • [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  • [F4]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Issuer

Bicara Therapeutics Inc.

CIK 0002023658

Entity typeother

Related Parties

1
  • filerCIK 0002034671

Filing Metadata

Form type
4
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 6:00 PM ET
Size
14.3 KB